APO-OLMESARTAN/AMLODIPINE/HCTZ 20/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 20/5/12.5 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-olmesartan/amlodipine/hctz 20/5/12.5 olmesartan medoxomil/amlodipine/hydrochlorothiazide 20/5/12.5 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; amlodipine besilate, quantity: 6.95 mg; olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; silicified microcrystalline cellulose; isopropyl alcohol; magnesium stearate; lactose monohydrate; povidone; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - apo-olmesartan/amlodipine/hctz 20/5/12.5 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

APO-OLMESARTAN/AMLODIPINE/HCTZ 40/10/25 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/25 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-olmesartan/amlodipine/hctz 40/10/25 olmesartan medoxomil/amlodipine/hydrochlorothiazide 40/10/25 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.9 mg; hydrochlorothiazide, quantity: 25 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; silicified microcrystalline cellulose; povidone; lactose monohydrate; pregelatinised maize starch; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/10/25 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

Amcofen 12.5 mg/125 mg film-coated tablets for dogs weighing at least 5 kg Ireland - English - HPRA (Health Products Regulatory Authority)

amcofen 12.5 mg/125 mg film-coated tablets for dogs weighing at least 5 kg

krka, d.d., novo mesto - milbemycin oxime; praziquantel - film-coated tablet - 12.5.125.0 mg/tablet - milbemycin oxime, combinations

Amcofen 2.5 mg/25 mg film-coated tablets for small dogs and puppies weighing at least 0.5 kg Ireland - English - HPRA (Health Products Regulatory Authority)

amcofen 2.5 mg/25 mg film-coated tablets for small dogs and puppies weighing at least 0.5 kg

krka, d.d., novo mesto - milbemycin oxime; praziquantel - film-coated tablet - 2.5,25 mg/tablet - milbemycin oxime, combinations

Mektix 12.5 mg/125 mg film-coated tablets for dogs weighing at least 5 kg Ireland - English - HPRA (Health Products Regulatory Authority)

mektix 12.5 mg/125 mg film-coated tablets for dogs weighing at least 5 kg

krka, d.d., novo mesto - milbemycin oxime; praziquantel - film-coated tablet - 12.5,125 mg/tablet - milbemycin oxime, combinations

Mektix 2.5 mg/25 mg film-coated tablets for small dogs and puppies weighing at least 0.5 kg Ireland - English - HPRA (Health Products Regulatory Authority)

mektix 2.5 mg/25 mg film-coated tablets for small dogs and puppies weighing at least 0.5 kg

krka, d.d., novo mesto - milbemycin oxime; praziquantel - film-coated tablet - 2.5,25 mg/tablet - milbemycin oxime, combinations

Milgusto 12.5 mg/125 mg film-coated tablets for dogs weighing at least 5 kg Ireland - English - HPRA (Health Products Regulatory Authority)

milgusto 12.5 mg/125 mg film-coated tablets for dogs weighing at least 5 kg

krka, d.d., novo mesto - milbemycin oxime; praziquantel - film-coated tablet - 12.5/125 mg/tablet - milbemycin oxime

Milgusto 2.5 mg/25 mg film-coated tablets for small dogs and puppies weighing at least 0.5 kg Ireland - English - HPRA (Health Products Regulatory Authority)

milgusto 2.5 mg/25 mg film-coated tablets for small dogs and puppies weighing at least 0.5 kg

krka, d.d., novo mesto - milbemycin oxime; praziquantel - film-coated tablet - 2.5/25 mg/tablet - milbemycin oxime

LACORESS lacosamide 100 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

lacoress lacosamide 100 mg film-coated tablet blister pack

cipla australia pty ltd - lacosamide, quantity: 100 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; hyprolose; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; macrogol 400 - lacoress (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

LACORESS lacosamide 200 mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

lacoress lacosamide 200 mg film-coated tablet blister pack

cipla australia pty ltd - lacosamide, quantity: 200 mg - tablet, film coated - excipient ingredients: hyprolose; crospovidone; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; macrogol 6000; macrogol 400; indigo carmine aluminium lake - lacoress (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.